|
 |
| home > ebr > autumn 2003 > review of the second annual biological forum, 2nd-3rd june 2003, palais des congress in lyon |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
The conference was organised by Access Events International (www.bio-access-events.com) and was dedicated to manufacturing strategies for biological-based therapies, encompassing facilities design and build including an example of creating a 60,000L mammalian cell culture facility. This was followed by a number of sessions based around manufacturing applications and techniques. Professor Rolf Werner (Boehringer Ingelheim) opened the meeting with a thorough review of the industry, showing that the world biotech industry mammalian fermenter capacity in 2005 will reach 1.4 million L.
The investment in one bioreactor has now reached around €50 million, with a time frame of five years from ground break to process validation. The decision to manufacture or outsource is a key strategic decision and is driven by access to capital and risk attitudes. John Machulski of Lonza then gave a specific example of building a 60,000L facility. The challenges of bringing together multi-disciplinary teams for project planning, design, construction and validation were considerable and an organisation without these internal capabilities embark on these projects at their peril.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
